Surrozen (SRZN) Equity Average (2020 - 2026)
Surrozen (SRZN) recorded quarterly Equity Average of -$233.0 million in Q1 2026, down 120.52% quarter-over-quarter from -$105.6 million in Q4 2025, and down 2866.44% on a YoY basis from $8.4 million in Q1 2025.
Surrozen (SRZN) Equity Average (2020 - 2026) Analysis & Trends
Surrozen's Equity Average history runs 7 years deep, the most recent figure standing at -$233.0 million for Q1 2026.
- In Q1 2026, Equity Average fell 2866.44% year-over-year to -$233.0 million; the TTM figure through Mar 2026 stood at -$233.0 million (down 2866.44% YoY), while the FY2025 annual figure was -$104.6 million, down 1363.32% from the prior year.
- Equity Average was -$233.0 million for Q1 2026 at Surrozen, down from -$105.6 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $106.2 million in Q1 2022 to a low of -$233.0 million in Q1 2026.
- Historically, Equity Average has averaged $19.1 million across 5 years, with a median of $34.0 million in 2024.
- The sharpest annual moves came in 2022 and 2026: Equity Average surged 233.53% in 2022, then sank 2866.44% in 2026.
- A 5-year view of Equity Average shows it stood at $76.7 million in 2022, then slumped by 45.62% to $41.7 million in 2023, then tumbled by 118.83% to -$7.9 million in 2024, then sank by 1244.6% to -$105.6 million in 2025, then plunged by 120.52% to -$233.0 million in 2026.
- The last three Equity Average figures came in at -$233.0 million (Q1 2026), -$105.6 million (Q4 2025), and $11.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 21.35 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 516.41 Mn |
| 10 | Surrozen | 225,877.86 | -106.68 Mn | - | -232.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -232.95 Mn |
| Dec 31, 2025 | -105.64 Mn |
| Sep 30, 2025 | 11.80 Mn |
| Jun 30, 2025 | 26.39 Mn |
| Mar 31, 2025 | -7.85 Mn |
| Dec 31, 2024 | -7.86 Mn |
| Sep 30, 2024 | 5.86 Mn |
| Jun 30, 2024 | 18.10 Mn |
| Mar 31, 2024 | 34.04 Mn |
| Dec 31, 2023 | 41.73 Mn |
| Sep 30, 2023 | 50.29 Mn |
| Jun 30, 2023 | 59.05 Mn |
| Mar 31, 2023 | 69.52 Mn |
| Dec 31, 2022 | 76.75 Mn |
| Sep 30, 2022 | 83.59 Mn |
| Jun 30, 2022 | 96.18 Mn |
| Mar 31, 2022 | 106.18 Mn |
| Dec 31, 2021 | 116.72 Mn |
| Sep 30, 2021 | 73.28 Mn |
| Jun 30, 2021 | 28.84 Mn |